My watch list


How the immune system becomes blind to cancer cells

CIBSS/Universität Freiburg, Michal Rössler

Cancer cells become invisible to the body's immune response. Unhindered by T cells (green), they can continue to replicate. Scientists have now described an important step in this process called "immune escape".

04-Feb-2020: T cells play a huge role in our immune system's fight against modified cells in the body that can develop into cancer. Phagocytes and B cells identify changes in these cells and activate the T cells, which then start a full-blown program of destruction. This functions well in many cases - unless the cancer cells mutate and develop a kind of camouflage that let them escape the immune system undetected. Researchers at the University of Freiburg and the Leibniz University Hannover (LUH) have now described how a key protein in this process known as "immune escape" becomes activated. The team headed by Prof. Dr. Maja Banks-Köhn and Prof. Dr. Wolfgang Schamel from the excellence clusters for biological signaling studies CIBSS and BIOSS at the University of Freiburg and the structural biologist Prof. Dr. Teresa Carlomagno from the LUH used biophysical, biochemical, and immunological methods in their research. Based on these insights, chemical biologist Banks-Köhn, hopes to develop drugs that intervene specifically in this activation mechanism. In the future, they could thereby improve established cancer treatments that rely on so-called immune checkpoint inhibitors. The team has recently published its research in a study in the scientific journal "Science Advances".

Checkpoint inhibitors are therapeutic antibodies that work by binding to the receptors of T cells. Proteins on the surface of the T cells called immune checkpoint receptors such as programmed cell death 1, or PD1, along with the signaling pathways that are triggered by them are what stop immune responses in a healthy body. This regulating mechanism prevents symptoms of inflammation from lasting too long and getting out of control. These symptoms include redness, swelling, and fever. Cancer cells take advantage of mechanisms such as these to render the body helpless while the cells multiply. Using cell cultures and interaction studies, the researchers from the two universities discovered that a signaling protein called SHP2 in T cells binds to PD1 in two specific places after it has been activated by a signal from cancer cells. It is this double binding to SHP2 that promotes the camouflaging effect and switches off the immune cells' response completely.

Antibodies that block immune inhibitors like PD1 are approved treatments for skin melanomas and lung carcinomas, and they prolong patients' lives. However, as a result, many patients suffer from autoimmune reactions. "Drugs that prevent the binding of SHP2 and PD1 could be used in the future to make side-effects less severe and to support, or to act as alternatives to, antibody treatments," says Banks-Köhn. She and Schamel studied the immune response of B cells and T cells by modifying SHP2 molecules, testing their predictions based crystal structure and magnetic resonance analysis of the team from the LUH. Their data shows precisely how and in what areas the SHP2 protein binds to PD1, thereby revealing a possible target area for drugs. "In our ongoing research project at the CIBSS - Centre for Integrative Biological Signalling Studies the next step is to decode the signaling pathway of PD1 - in other words, where the proteins are located in the cell, where they bind, and within what time frame the signals take effect," Banks-Köhn says.

Original publication:
Marasco, M./Berteotti, A./Weyershaeuser, J./Thorausch, N./Sikorska. J./Krausze, J./Brandt, H. J./Kirkpatrick, J./Rios, P./Schamel, W. W./Köhn, M./Carlomagno, T. (2020): "Molecular mechanism of SHP2 activation by PD-1 stimulation."; Science Advances 2020/6.

Facts, background information, dossiers

  • cancer cells
  • therapeutic antibodies
  • immune system
  • cancer

More about Uni Freiburg

  • News

    Innocent and highly oxidizing

    Chemical oxidation, the selective removal of electrons from a substrate, represents one of the most important transformations in chemistry. However, most common oxidants often show disadvantages such as undesired side reactions. The chemist Marcel Schorpp and colleagues from the group of Pr ... more

    Programming with the Light Switch

    In the development of autonomous systems and materials, self-assembling molecular structures controlled by chemical reaction networks are increasingly important. However, there is a lack of simple external mechanisms that ensure that the components of these reaction networks can be activate ... more

    Coronavirus data analysis

    Dr. Wolfgang Maier and Dr. Björn Grüning from the University of Freiburg, together with researchers from universities in Belgium, Australia and the USA, have reviewed the previously available data on sequences of the novel coronavirus and published their analyses on the open source platform ... more

  • q&more articles

    Modular biofactories at the cellular level

    Despite his love for complex molecular architectures, this „dyed-in-the-wool“ bio-organic chemist has never embraced the conventional segregation of synthetic polymers and bio­logical macromolecules. All molecules are composed of atoms, after all. Why make an artificial distinction? Why not ... more


    From a pluripotent stem cell a muscle cell or a liver cell can form, which despite their difference in appearance, are genetically identical. From one and the same genotype, therefore, the most diverse phenotypes can be formed – epigenetics is making it possible! It is a very exciting area ... more

  • Authors

    Dr. Stefan Schiller

    Stefan M. Schiller studied chemistry at Gießen (Mainz, Germany) and the University of Massachusetts, majoring in macromolecular chemistry and biochemistry. For his doctorate in biomimetic membrane systems he worked till 2003 at the Max Planck Institute for Polymer Research in Mainz. Researc ... more

    Julia M. Wagner

    Julia M. Wagner studied pharmacy in Freiburg (licensure 2008). Since 2008 she is a PhD student and research assistant in the group of Professor Dr. M. Jung. Her research focuses ­on the cellular effects of histone deacetylase inhibitors. more

    Prof. Dr. Manfred Jung

    Manfred Jung is a graduate of the University of Marburg, where he studied pharmacy (licensure  1990) and obtained his doctorate in pharmaceutical chemistry with Prof. Dr. W. Hanefeld. After a post-doctorate at the University of Ottawa, Canada, he began with independent research in 1994 ­at ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:


Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE